Recent from talks
Emicizumab
Knowledge base stats:
Talk channels stats:
Members stats:
Emicizumab
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). Emicizumab is a bispecific factor IXa- and factor X-directed antibody.
Emicizumab was first approved by the U.S. Food and Drug Administration (FDA) in November 2017 for routine prophylaxis in patients with hemophilia A who have developed factor VIII inhibitors. In October 2018, the FDA expanded approval, under the breakthrough therapy designation , to include all patients with hemophilia A, regardless of inhibitor status. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines.
Emicizumab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
Emicizumab is administered as a subcutaneous injection with flexible dosing options. The drug can be administered once weekly, every two weeks, or every four weeks, providing patients and healthcare providers with dosing flexibility based on individual needs and preferences.
The long elimination half-life of approximately 28-32 days supports the extended dosing intervals, making it more convenient compared to traditional factor VIII replacement therapy, which typically requires more frequent administration.
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
The long elimination half-life of approximately 28-32 days supports the extended dosing intervals, making it more convenient compared to traditional factor VIII replacement therapy, which typically requires more frequent administration.
Emicizumab is a bispecific antibody that simultaneously binds to activated coagulation factor IX (FIXa) and factor X (FX), bringing these coagulation factors into spatial proximity to facilitate the activation of factor X. This mechanism mimics the natural cofactor function of activated factor VIII (FVIIIa) in the coagulation cascade, effectively replacing the missing or deficient clotting factor in patients with hemophilia A.
Hub AI
Emicizumab AI simulator
(@Emicizumab_simulator)
Emicizumab
Emicizumab, sold under the brand name Hemlibra, is a humanized bispecific monoclonal antibody for the treatment of haemophilia A, developed by Genentech and Chugai (both organizations are subsidiaries of Hoffmann-La Roche). Emicizumab is a bispecific factor IXa- and factor X-directed antibody.
Emicizumab was first approved by the U.S. Food and Drug Administration (FDA) in November 2017 for routine prophylaxis in patients with hemophilia A who have developed factor VIII inhibitors. In October 2018, the FDA expanded approval, under the breakthrough therapy designation , to include all patients with hemophilia A, regardless of inhibitor status. The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication. It is on the World Health Organization's List of Essential Medicines.
Emicizumab is indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in people with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
Emicizumab is administered as a subcutaneous injection with flexible dosing options. The drug can be administered once weekly, every two weeks, or every four weeks, providing patients and healthcare providers with dosing flexibility based on individual needs and preferences.
The long elimination half-life of approximately 28-32 days supports the extended dosing intervals, making it more convenient compared to traditional factor VIII replacement therapy, which typically requires more frequent administration.
The most common adverse reactions (incidence ≥10%) are injection site reactions, headache, and arthralgia.
The long elimination half-life of approximately 28-32 days supports the extended dosing intervals, making it more convenient compared to traditional factor VIII replacement therapy, which typically requires more frequent administration.
Emicizumab is a bispecific antibody that simultaneously binds to activated coagulation factor IX (FIXa) and factor X (FX), bringing these coagulation factors into spatial proximity to facilitate the activation of factor X. This mechanism mimics the natural cofactor function of activated factor VIII (FVIIIa) in the coagulation cascade, effectively replacing the missing or deficient clotting factor in patients with hemophilia A.
Recent media